Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Therapeutic Hydrocortisone

Review the clinical trials studying therapeutic hydrocortisone on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 113 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 74 locations
Talazoparib in Combination with Chemotherapy for the Treatment of Pediatric Patients with Relapsed or Refractory AML, the PARPAML Trial
Status: Active
Location: 10 locations
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Status: Active
Location: 20 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 6 locations
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Status: Active
Location: 3 locations
Risk Categorization for Treatment Assignment in Children and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma, the INITIALL Trial
Status: Active
Location: 3 locations
Inotuzumab Ozogamicin in Treating Patients with MRD Positive CD22+ Relapsed B Cell Acute Lymphoblastic Lymphoma
Status: Active
Location: 2 locations
Inotuzumab Ozogamicin and Blinatumomab with Standard Chemotherapy in Treating Newly Diagnosed Patients with B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Status: Active
Location: 2 locations
CPX-351 (VYXEOS) for the Treatment of Secondary Myeloid Neoplasms in Patients Under 22 Years Old
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Mini Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for the Treatment of Relapsed B-Cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Ziftomenib with Venetoclax and Gemtuzumab Ozogamicin for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Status: Active
Location: See ClinicalTrials.gov
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon